UA81642C2 - Кальцилитическое соединение, способ лечения и способ повышения уровней паратиреоидного гормона - Google Patents

Кальцилитическое соединение, способ лечения и способ повышения уровней паратиреоидного гормона

Info

Publication number
UA81642C2
UA81642C2 UAA200505005A UA2005005005A UA81642C2 UA 81642 C2 UA81642 C2 UA 81642C2 UA A200505005 A UAA200505005 A UA A200505005A UA 2005005005 A UA2005005005 A UA 2005005005A UA 81642 C2 UA81642 C2 UA 81642C2
Authority
UA
Ukraine
Prior art keywords
group
ris
halogen
alkyl
parathyroid hormone
Prior art date
Application number
UAA200505005A
Other languages
English (en)
Ukrainian (uk)
Inventor
Роберт В. Маркус
Линда Н. Касиллас
Джоши М. Раманджул
Джеймс Францис Каллахан
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of UA81642C2 publication Critical patent/UA81642C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA200505005A 2002-11-26 2003-11-25 Кальцилитическое соединение, способ лечения и способ повышения уровней паратиреоидного гормона UA81642C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26
PCT/US2003/037461 WO2004047751A2 (en) 2002-11-26 2003-11-25 Calcilytic compounds

Publications (1)

Publication Number Publication Date
UA81642C2 true UA81642C2 (ru) 2008-01-25

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505005A UA81642C2 (ru) 2002-11-26 2003-11-25 Кальцилитическое соединение, способ лечения и способ повышения уровней паратиреоидного гормона

Country Status (33)

Country Link
US (6) US7514473B2 (ru)
EP (1) EP1569892B1 (ru)
JP (1) JP4489597B2 (ru)
KR (2) KR20050086786A (ru)
CN (1) CN1325466C (ru)
AP (1) AP2113A (ru)
AR (1) AR042132A1 (ru)
AU (1) AU2003291157C1 (ru)
BR (1) BR0316544A (ru)
CA (1) CA2507226C (ru)
CO (1) CO5570664A2 (ru)
CY (1) CY1113083T1 (ru)
DK (1) DK1569892T3 (ru)
EA (1) EA009603B1 (ru)
ES (1) ES2388277T3 (ru)
HK (1) HK1082914A1 (ru)
IL (1) IL168704A (ru)
IS (1) IS2897B (ru)
MA (1) MA27528A1 (ru)
MX (1) MXPA05005574A (ru)
MY (1) MY143244A (ru)
NO (1) NO332304B1 (ru)
NZ (1) NZ540275A (ru)
OA (1) OA12962A (ru)
PE (1) PE20040845A1 (ru)
PL (1) PL211571B1 (ru)
PT (1) PT1569892E (ru)
SI (1) SI1569892T1 (ru)
TW (1) TWI316511B (ru)
UA (1) UA81642C2 (ru)
UY (1) UY28089A1 (ru)
WO (1) WO2004047751A2 (ru)
ZA (1) ZA200504104B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
WO2005077886A1 (en) * 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
UY30801A1 (es) * 2006-12-18 2008-07-03 Smithkline Beecham Corp Compuestos calciliticos
CN102056897B (zh) * 2008-06-05 2014-05-07 旭化成制药株式会社 磺酰胺化合物及其用途
SG172141A1 (en) * 2008-12-24 2011-07-28 Daiichi Sankyo Co Ltd Indanyl compounds
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (en) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (ru)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (ru) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE69733649T2 (de) 1996-04-09 2006-05-18 NPS Pharmaceuticals, Inc., Salt Lake City Calcylitische verbindungen
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
US20020019440A1 (en) 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
WO1998044925A1 (en) 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
DE19913753A1 (de) 1998-04-01 1999-10-07 Mannesmann Rexroth Ag Verfahren zur Bildung des Mittelwertes
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
WO2000009491A1 (en) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
US6291459B1 (en) 1998-08-12 2001-09-18 Smithkline Beecham Corporation Calcilytic compounds
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU6050000A (en) 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
IL154058A0 (en) 2000-07-21 2003-07-31 Smithkline Beecham Corp Calcilytic compounds
AU2002239489A1 (en) 2000-10-25 2002-05-21 Smithkline Beecham Corporation Calcilytic compounds
WO2002034204A2 (en) 2000-10-25 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds
WO2002072760A2 (en) 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pcra helicase inhibitors
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US7491728B2 (en) 2003-04-07 2009-02-17 Smithkline Beecham Corp. Pyrimidinone compounds as calcilytics
AU2004266705A1 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
TW200524892A (en) 2003-09-24 2005-08-01 Glaxo Group Ltd Calcilytic compounds
WO2005030746A1 (en) 2003-09-24 2005-04-07 Glaxo Group Limited Calcilytic compounds
WO2005077892A1 (en) 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
AU2005304770A1 (en) 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
US20080306041A1 (en) 2005-01-21 2008-12-11 Garvey David S Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use

Also Published As

Publication number Publication date
EP1569892A2 (en) 2005-09-07
EP1569892A4 (en) 2010-09-15
EA200500878A1 (ru) 2005-10-27
US20060058391A1 (en) 2006-03-16
US9227914B2 (en) 2016-01-05
CY1113083T1 (el) 2016-04-13
EP1569892B1 (en) 2012-06-13
US20110054021A1 (en) 2011-03-03
US20090163589A1 (en) 2009-06-25
US8980950B2 (en) 2015-03-17
US8586631B2 (en) 2013-11-19
ZA200504104B (en) 2006-03-29
AU2003291157C1 (en) 2011-05-12
KR101142697B1 (ko) 2012-05-10
PL211571B1 (pl) 2012-05-31
SI1569892T1 (sl) 2012-09-28
UY28089A1 (es) 2004-06-30
NZ540275A (en) 2007-11-30
CO5570664A2 (es) 2005-10-31
NO332304B1 (no) 2012-08-20
KR20050086786A (ko) 2005-08-30
NO20053071L (no) 2005-06-22
JP4489597B2 (ja) 2010-06-23
IL168704A (en) 2010-12-30
EA009603B1 (ru) 2008-02-28
MA27528A1 (fr) 2005-09-01
JP2006507348A (ja) 2006-03-02
US8399517B2 (en) 2013-03-19
MXPA05005574A (es) 2005-07-27
CN1741985A (zh) 2006-03-01
US7829594B2 (en) 2010-11-09
AP2113A (en) 2010-03-04
AU2003291157B2 (en) 2011-01-20
TW200510276A (en) 2005-03-16
MY143244A (en) 2011-04-15
BR0316544A (pt) 2005-10-04
US20130158114A1 (en) 2013-06-20
CA2507226A1 (en) 2004-06-10
TWI316511B (en) 2009-11-01
PL376965A1 (pl) 2006-01-09
CN1325466C (zh) 2007-07-11
CA2507226C (en) 2011-11-15
WO2004047751A2 (en) 2004-06-10
US7514473B2 (en) 2009-04-07
ES2388277T3 (es) 2012-10-11
PE20040845A1 (es) 2004-11-28
OA12962A (en) 2006-10-13
AU2003291157A1 (en) 2004-06-18
DK1569892T3 (da) 2012-08-27
IS7880A (is) 2005-06-02
HK1082914A1 (en) 2006-06-23
US20150183723A1 (en) 2015-07-02
PT1569892E (pt) 2012-09-06
WO2004047751A3 (en) 2004-08-19
IS2897B (is) 2014-09-15
AR042132A1 (es) 2005-06-08
US20140057980A1 (en) 2014-02-27
AP2005003320A0 (en) 2005-06-30
KR20110124806A (ko) 2011-11-17

Similar Documents

Publication Publication Date Title
BG106738A (en) A method for chemoprevention of prostate cancer
EG25822A (en) Quinolinyl-pyrrolopyrazoles
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
SE0002320D0 (sv) Malignant tumors
UA81642C2 (ru) Кальцилитическое соединение, способ лечения и способ повышения уровней паратиреоидного гормона
EP1839662A4 (en) ANTITUMOR AGENT
MXPA04006033A (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina.
IS2387B (is) Æxliseyðandi efni
MY134929A (en) Novel imidazole derivatives, production method thereof and use thereof
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
RU2003128068A (ru) 2-тиозамещенные производные имидазола и их применение в фармации
AU6220300A (en) Benzofurylpiperazine serotonin agonists
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
KR950702534A (ko) 콜레스테롤 생합성 억제제로서의 신규한 피페리딜 아미드, 설폰아미드 및 설폭스아미드(Novel piperidyl amides, sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis)
WO2005060571A3 (en) Antiprotozoal imidazopyridine compounds
MXPA03005374A (es) Carbazoles antitumorales.
EA200400533A1 (ru) Новые соединения гидроксиалкилиндолокарбазола, способ их получения и фармацевтические композиции, которые их содержат
IL156768A0 (en) Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
ATE380810T1 (de) Protein-tyrosine-kinase-inhibitoren
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
SE9800905D0 (sv) New therapy in glomerulonephritis
HK1085744A1 (en) Steroid compounds with anti-tumor activity
PT1098645E (pt) Composicoes compreendendo derivados do acido fenilaminotiofenacetico para o tratamento do sindroma da insuficiencia respiratoria do adulto (ards) e do sindroma da insuficiencia respiratoria da crianca (irds)
EP0116255A3 (en) Treatment of migraine with n-alkyl-piperidinyl benzoate derivatives